Autolus Therapeutics (AUTL) Revenue & Revenue Breakdown
Autolus Therapeutics Revenue Highlights
Latest Revenue (Y)
$75.56M
Latest Revenue (Q)
$45.67M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Autolus Therapeutics Revenue by Period
Autolus Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $75.56M | 646.68% |
| 2024-12-31 | $10.12M | 496.00% |
| 2023-12-31 | $1.70M | -72.59% |
| 2022-12-31 | $6.19M | 311.02% |
| 2021-12-31 | $1.51M | -12.13% |
| 2020-12-31 | $1.72M | -41.02% |
| 2019-12-31 | $2.91M | 178.19% |
| 2018-09-30 | $1.05M | -38.25% |
| 2017-09-30 | $1.69M | 39.69% |
| 2016-09-30 | $1.21M | 1187.83% |
| 2015-09-30 | $94.11K | - |
Autolus Therapeutics generated $75.56M in revenue during NA 2025, up 646.68% compared to the previous quarter, and up 4406.07% compared to the same period a year ago.
Autolus Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-06-30 | $45.67M | 74.20% |
| 2026-03-31 | $26.22M | 8.10% |
| 2025-12-31 | $24.25M | 14.44% |
| 2025-09-30 | $21.19M | 1.30% |
| 2025-06-30 | $20.92M | 132.94% |
| 2025-03-31 | $8.98M | 30872.41% |
| 2024-12-31 | $29.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $10.09M | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2023-09-30 | $406.00K | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $1.29M | -66.22% |
| 2022-12-31 | $3.83M | 61.46% |
| 2022-09-30 | $2.37M | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $180.00K | -23.73% |
| 2021-09-30 | $236.00K | -85.65% |
| 2021-06-30 | $1.65M | 511.52% |
| 2021-03-31 | $269.00K | -33.42% |
| 2020-12-31 | $404.00K | -40.59% |
| 2020-09-30 | $680.00K | 132.08% |
| 2020-06-30 | $293.00K | -13.31% |
| 2020-03-31 | $338.00K | 9.39% |
| 2019-12-31 | $309.00K | 4.04% |
| 2019-09-30 | $297.00K | -12.13% |
| 2019-06-30 | $338.00K | -82.79% |
| 2019-03-31 | $1.96M | 563.51% |
| 2018-12-31 | $296.00K | -3.58% |
| 2018-09-30 | $307.00K | -30.70% |
| 2018-06-30 | $443.00K | 3.99% |
| 2018-03-31 | $426.00K | 4.93% |
| 2017-09-30 | $406.00K | - |
| 2017-06-30 | $406.00K | -7.83% |
| 2017-03-31 | $440.50K | - |
| 2016-12-31 | $440.50K | - |
Autolus Therapeutics generated $45.67M in revenue during Q2 2026, up 74.20% compared to the previous quarter, and up 508.48% compared to the same period a year ago.
Autolus Therapeutics Revenue Breakdown
Autolus Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Product | $74.32M | - | - | - | - |
| License | $1.07M | $10.12M | $1.70M | $3.50M | - |
| Royalty | - | - | - | - | - |
| Grant | - | - | - | $166.00K | $823.00K |
Autolus Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (98.58%), and License (1.42%).
Quarterly Revenue by Product
| Product/Service | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| License | $17.00K | $1.02M | $50.00K | $20.00K | - | $10.10M | - | $242.00K | - | - | - |
| Product | $45.67M | $23.27M | $21.14M | $20.92M | $8.98M | - | - | - | - | - | - |
| Reportable Segment | - | $26.22M | - | - | - | - | - | - | - | - | - |
| Grant | - | - | - | - | - | - | - | - | - | $1.03M | $438.00K |
Autolus Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Product (99.96%), and License (0.04%).
Autolus Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| UNITED STATES | $1.02M | $1.35M | $6.19M | $1.51M | - |
| Europe | $50.00K | $10.12M | - | - | - |
Autolus Therapeutics's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (95.33%), and Europe (4.67%).
Quarterly Revenue by Country
| Country | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Mar 24 | Sep 20 |
|---|---|---|---|---|---|---|
| Europe | - | $50.00K | - | - | - | - |
| UNITED STATES | - | $20.92M | $8.98M | - | - | - |
| GERMANY | - | - | - | - | $10.09M | - |
| License | - | - | - | - | - | $242.00K |
| Grant | - | - | - | - | - | $438.00K |
Autolus Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AUTL | Autolus Therapeutics | $75.56M | $45.67M |
| ADCT | ADC Therapeutics | $73.55M | $18.63M |
| QSI | Quantum-Si | $2.44M | $344.00K |
| RAPT | RAPT Therapeutics | - | - |
| SLDB | Solid Biosciences | - | - |
| AURA | Aura Biosciences | - | - |
| RCKT | Rocket Pharmaceuticals | - | - |
| NMRA | Neumora Therapeutics | - | - |
| ANNX | Annexon | - | - |
| BNTC | Benitec Biopharma | - | - |
| LBRX | LB Pharmaceuticals | - | - |